Yuli 2021: Bincika sabbin magunguna a cikin maganin ciwon daji. Kowace shekara, bayan nazarin gwaje-gwaje da sauran muhimman abubuwa, da USFDA ya yarda da magunguna, don haka masu ciwon daji yanzu za su iya yarda cewa magani ya kusa.
A cikin 'yan shekarun nan, abubuwa da yawa sun faru don canza yanayin cutar kuma za a magance su. Sakamakon haka, mutanen da ke fama da cutar kansa da likitocin su suna da ƙarin zaɓin da za su zaɓa daga ciki da ƙari akan hanya.
Duba: Kudin maganin ciwon daji a Indiya
Ƙarfin ƙwayoyin ku don guje wa tsarin garkuwar jikin ku abu ɗaya ne da ke sa yaƙi da cutar kansa ya zama ƙalubale. Jikin ku kawai baya ganin su a matsayin barazana, ko kuma ba zai iya aiki ba don yaƙar su sosai.
Amma waɗannan sel suna "alama" ta wasu magungunan rigakafi na zamani, don haka suna da sauƙin samu. Waɗannan magunguna kuma na iya sa garkuwar jikinka ta yi ƙarfi ta yadda za su iya kai hari ga ciwace-ciwace.
Irin wannan magani ya riga ya yi tasiri a kan wasu nau'in ciwon daji. Magunguna da yawa suna cikin ayyukan.
Wani nau'in maganin jinsi da ake kira CAR T-cell far an yarda da FDA. Yana amfani da wasu ƙwayoyin jikinku don magance kansar ku, wanda ake kira T cells. Ta hanyar shigar da sabbin kwayoyin halitta, likitoci sun cire kwayoyin daga jinin ku kuma canza su don su iya ganowa da lalata kwayoyin cutar kansa da sauri.
Duba: Farashin CAR T-cell far don m lymphoblastic cutar sankarar bargo (ALL) a Isra'ila
A halin yanzu an yarda da miyagun ƙwayoyi da ake kira tisagenlecleucel (Kymriah) don maganin cutar sankarar jini mai tsanani na B-cell a cikin yara da matasa masu girma har zuwa shekaru 25 da ba su ci gaba da wasu hanyoyin kwantar da hankali ba. Amma ga manya da sauran nau'ikan ciwon daji, masana kimiyya suna aiki akan wani nau'in maganin CAR T-cell.
Tisagenleucel da axicabtagene (Yescarta) An yarda da su duka don magance wasu nau'in lymphoma na B-cell na manya waɗanda wasu jiyya ba su iya taimakawa ba.
Duba: Farashin CAR T-cell far a China
Wani sabon maganin da ake kira brexucabtagene autoleucel (Tecartus) ya kasance kwanan nan FDA ta amince da marasa lafiya tare da lymphoma na mantle cell wadanda ba su ci gaba da wasu hanyoyin kwantar da hankali ba ko kuma sun dawo bayan jiyya.
Ciwon daji har yanzu wani sirri ne da ba a warware shi ba, kuma masana kimiyya, likitoci, da kamfanoni a duniya har yanzu suna neman samun mafi kyawun maganin wannan cuta mai kisa. Ya zuwa yanzu, maganin kashe kwayoyin cuta na daya daga cikin kayan aiki mafi inganci a hannun kwararrun kwararru kan cutar daji a Indiya da ma duniya baki daya, wadanda idan aka gano su da wuri, za su iya yakar cutar sosai. Mun ga sabbin magunguna da yawa sun fito a cikin ƴan shekarun da suka gabata don yaƙar ƙwayoyin cutar kansa. Wannan kuma yana buƙatar maganin da aka yi niyya wanda ke nufin kai hari ga sel musamman, yana barin ƙwayoyin al'ada su sami ƙarancin lalacewa. USFDA ta kuma amince da amincewarta ta farko don maganin canjin kwayoyin halitta a wannan shekara a cikin 2017, tana canza ƙwayoyin t na marasa lafiya don yin tasiri sosai kan yaƙar kansa.
A cikin 2017, USFDA ta ba da izini ga wasu magungunan waɗanda suka yi imanin za su yi babban bambanci a cikin maganin cutar kansa. Su ne:
- Bavencio (Avelumab) - Ciwon daji na mafitsara
- Kisqali (Ribociclib) - Ciwon daji na mama
- Nerlynx (Neratinib) - Ciwon nono
- Rydapt (Midostaurin) - Cutar sankarar bargo
- Besponsa (Inotuzumab Ozagamicin) - Cutar sankarar bargo
- Kymiah (Tisagenlecleucel) - Cutar sankarar bargo
- Tafinlar (Dabrafanib) - Ciwon daji na huhu
- Mekinist (Trametinib) - Ciwon huhu
- Opdivo (Livolumab) - Ciwon daji na hanta
- Yescarta (Axicabtagene ciloleucel) - Lymphoma
- Calquence (Acalabrutunib) - Lymphoma
- Bavencio (Avelumab) - Ciwon ƙwayar ƙwayar ƙwayar ƙwayar cuta ta Merkel
- Zejula (Niraparib) - Ciwon Ovarian
- Keytruda (Pembrolizumab) - Ciwon daji
